Promomed Group is a leading innovative biopharmaceutical company with growth potential in promising and high-margin segments of the pharmaceutical market. The company structure includes its own unique R&D center and the high-tech Biokhimik plant. Due to this, Promomed implements the concept of a full production cycle “from idea — to molecule — from molecule — to patient”. Promomed promptly responds to the current needs of the industry, and also introduces the latest technologies to create innovative medications.

The company is the first in Russia in terms of the number of medical studies and production of endocrinological medications (more than 50% of the excess weight therapy market). It is also TOP-2 in the segment of antibiotics and medications to combat infections, HIV, and hepatitis.

The company is developing a diversified portfolio of more than 330 medications in more than 7 different nosologies, which includes blockbuster medications and innovative biotechnological medications that have no analogues on the Russian market. Based on its own developments, the company produces medications for the treatment of socially significant diseases — oncology, diabetes, obesity, etc. More than 80% of the medications produced by the company are included in the state list of vital and essential medications (VED).

Our own R&D hub is the core of breakthrough solutions in the field of healthcare and the basis for the company’s business development. It includes laboratories for the development of finished medications (biotechnological and small molecule based) and pharmaceutical substances, an analytical laboratory, a registration service and a transfer coordination center.

Thanks to its own innovative chemical and biotechnologies, as well as modern production facilities, the company is an active participant in the system of ensuring national medication safety and import independence of the country.

https://promomed.ru/en